8 enrolling by invitation. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Enrolling by invitation 8 |
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis IMG-007 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Enrolling by invitation | Inmagene LLC | 400 | 2026-06-05 | 2026-07-29 |
| Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC - Anaphylaxis, Allergy | Phase 1 / Phase 2 | Enrolling by invitation | Nasus Pharma | 50 | 2025-11-03 | 2025-11-14 |
| Efficacy of Topical Cannabidiol for Eczema Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream - Chronic Pruritus, Eczema | Phase 2 | Enrolling by invitation | Khon Kaen University | 60 | 2025-05-01 | 2026-08-04 |
| A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma HSK31858, Placebo - Bronchial Asthma | Phase 2 | Enrolling by invitation | Haisco Pharmaceutical Group Co., Ltd. | 219 | 2024-10-22 | 2024-12-24 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma Lunsekimig - Asthma | Phase 2 | Enrolling by invitation | Sanofi | 900 | 2024-09-30 | 2026-09-21 |
| A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis JYP0061 15 mg, JYP0061 30 mg, Placebo - Moderate-to-severe Atopic Dermatitis | Phase 2 | Enrolling by invitation | Guangzhou JOYO Pharma Co., Ltd | 120 | 2023-12-27 | 2025-03-20 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
Dermatitis, Atopic (3) · Asthma (2) · Eczema (2) · Anaphylaxis (1) · Angioedemas, Hereditary (1) · Chronic Inducible Urticaria (1) · Chronic Urticaria (1) · Dermatitis (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1) · Immune System Diseases (1) · Skin Diseases (1)
Hypersensitivity, Immediate (8) · Immune System Diseases (7) · Skin and Connective Tissue Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Skin Diseases (4) · Skin Diseases, Eczematous (3) · Skin Diseases, Genetic (3) · Bronchial Diseases (2) · Dermatitis (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Respiratory Hypersensitivity (2) · Respiratory Tract Diseases (2)
Cannabidiol (1) · Epinephrine (1) · Histamine H1 Antagonists, Non-Sedating (1) · Triamcinolone (1) · apremilast (1)
Guangzhou JOYO Pharma Co., Ltd (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Inmagene LLC (1) · Khon Kaen University (1) · Nasus Pharma (1) · Pharvaris Netherlands B.V. (1) · Rashid Latif Medical College (1) · Sanofi (1)
Canada (4) · China (3) · United States (3) · Argentina (2) · Brazil (2) · Germany (2) · Hungary (2) · Israel (2) · Italy (2) · Japan (2) · Poland (2) · South Africa (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2)
Mark L Freedman, MD, FRCPC (1) · Merrium Mahrukh, MBBS (1)
2023 (1), 2025 (1)